Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Hans-Christoph DienerRalph L SaccoJ Donald EastonChristopher B GrangerRichard A BernsteinShinichiro UchiyamaJörg KreuzerLisa CroninDaniel CottonClaudia GrauerMartina BrueckmannMarina ChernyatinaGeoffrey DonnanJosé M FerroMartin GrondBernd KallmünzerJerzy KrupinskiByung-Chul LeeRobin LemmensJaime MasjuanMiroslav OdinakJeffrey L SaverPeter D SchellingerDanilo ToniKazunori Toyodanull nullPublished in: The New England journal of medicine (2019)
In patients with a recent history of embolic stroke of undetermined source, dabigatran was not superior to aspirin in preventing recurrent stroke. The incidence of major bleeding was not greater in the dabigatran group than in the aspirin group, but there were more clinically relevant nonmajor bleeding events in the dabigatran group. (Funded by Boehringer Ingelheim; RE-SPECT ESUS ClinicalTrials.gov number, NCT02239120.).